A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease prog...

Update Il y a 4 ans
Reference: EUCTR2006-004634-32

A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess Overall survival (OS)


Inclusion criteria

  • Metastatic colorectal cancer